Build status - In Progress

An Open-label Clinical Study to Evaluate the Safety and Tolerability of Treprostinil Inhalation Powder (TreT) in Subjects with Pulmonary Arterial Hypertension Currently Using Tyvaso

Recruiting
99 years or below
All
Phase 1
6 participants needed
1 Location

Brief description of study

This Phase 1b, open-label, multicenter study will be conducted to evaluate the safety and tolerability of treprostinil inhalation powder (TreT) in subjects with PAH currently ssing Tyvaso. A minimum of 45 patients from 15 sites in the US will be enrolled in the study.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Medical Research
  • Age: 99 years or below
  • Gender: All
Updated on 10 Jun 2020. Study ID: 833451

Find a site

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Email

View email

Phone

Phone country flag

View phone
Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Preferred way of contact
Race
Ethnicity
Other language

Interested in the study

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center